Literature DB >> 189919

Inhibition of leukocyte migration by tumor-associated antigen in soluble extracts of human hepatoma.

C Lee, S Chen, T Lin.   

Abstract

The leukocyte migration inhibition assay was used to detect cell-mediated immune reaction of hepatoma patients. Extraction of 3 pairs of human hepatoma tissue and normal liver tissue was made by 3 M KCI solution, and soluble hepatoma antigens were used to test against leukocytes of 18 hepatoma patients by the leukocyte migration inhibition assay. In all, 25 tests were performed; most of them were allogenic, and only 3 tests were autologous. Migration inhibition was observed in 13 of 25 tests, and there were only a few cases of migration inhibition in the control groups. It was concluded that tumor-associated antigen of human hepatoma was contained in the 3 M KCI extract of hepatoma tissue and that tumor-associated antigen of human hepatoma was shared by some hepatoma patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 189919

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Impaired T cell function and decreased natural killer activity in patients with liver cirrhosis and their significance in the development of hepatocellular carcinoma.

Authors:  T Morizane; T Watanabe; K Tsuchimoto; M Tsuchiya
Journal:  Gastroenterol Jpn       Date:  1980

2.  Relationship between general or specific immunoreactivity and prognosis in postoperative patients with hepatocellular carcinoma.

Authors:  H Yamasaki; E Okamoto; T Komatsu; Y Manabe; S Shinka
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Leucocyte migration inhibition by tumour-associated antigens in human bladder carcinoma.

Authors:  D F Meleady; M R Butler; J F Greally; G M Mullins
Journal:  Ir J Med Sci       Date:  1980-10       Impact factor: 1.568

4.  Evaluation of leucocyte adherence inhibition in hepatocellular carcinoma.

Authors:  G M Dusheiko; M C Kew; A R Rabson
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.